Results from the phase 3 ADMIRAL trial were announced during the American Association for Cancer Research annual meeting.
Presenters at the 2019 annual meeting's opening plenary spoke about merging technologies in order to individualize care for their patients.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
Investigators and commercial firms presenting at the recent AACR meeting highlighted how heterogeneous both the technology and the application of liquid biopsy remains.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.